Free Trial

Stryker (SYK) Competitors

$341.09
+0.57 (+0.17%)
(As of 05/31/2024 ET)

SYK vs. ABT, ISRG, BSX, MDT, BDX, EW, DXCM, IDXX, RMD, and STE

Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.

Stryker vs.

Abbott Laboratories (NYSE:ABT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking.

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$40.11B4.43$5.72B$3.2131.83
Stryker$20.50B6.34$3.17B$8.7638.94

Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.2%. Stryker pays an annual dividend of $3.20 per share and has a dividend yield of 0.9%. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Stryker pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has raised its dividend for 53 consecutive years and Stryker has raised its dividend for 31 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Abbott Laboratories presently has a consensus target price of $120.64, indicating a potential upside of 18.05%. Stryker has a consensus target price of $370.58, indicating a potential upside of 8.65%. Given Stryker's higher possible upside, research analysts clearly believe Abbott Laboratories is more favorable than Stryker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abbott Laboratories
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
Stryker
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.79

Abbott Laboratories has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Stryker has a net margin of 16.03% compared to Stryker's net margin of 13.96%. Abbott Laboratories' return on equity of 23.05% beat Stryker's return on equity.

Company Net Margins Return on Equity Return on Assets
Abbott Laboratories13.96% 20.18% 10.60%
Stryker 16.03%23.05%10.88%

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 1.1% of Abbott Laboratories shares are held by insiders. Comparatively, 5.9% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Abbott Laboratories had 4 more articles in the media than Stryker. MarketBeat recorded 23 mentions for Abbott Laboratories and 19 mentions for Stryker. Abbott Laboratories' average media sentiment score of 0.96 beat Stryker's score of 0.48 indicating that Stryker is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abbott Laboratories
11 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Stryker
13 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abbott Laboratories received 30 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.64% of users gave Abbott Laboratories an outperform vote while only 64.49% of users gave Stryker an outperform vote.

CompanyUnderperformOutperform
Abbott LaboratoriesOutperform Votes
920
69.64%
Underperform Votes
401
30.36%
StrykerOutperform Votes
890
64.49%
Underperform Votes
490
35.51%

Summary

Stryker beats Abbott Laboratories on 13 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYK vs. The Competition

MetricStrykerSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$129.94B$3.86B$5.11B$17.81B
Dividend Yield0.94%1.82%2.75%3.55%
P/E Ratio38.9410.03120.3622.67
Price / Sales6.3471.082,428.4511.15
Price / Cash25.4048.1735.0418.95
Price / Book6.785.075.525.90
Net Income$3.17B$4.50M$105.88M$976.46M
7 Day Performance1.65%1.27%1.13%0.62%
1 Month Performance3.95%0.10%1.42%4.79%
1 Year Performance22.44%-17.03%4.04%24.00%

Stryker Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABT
Abbott Laboratories
4.9488 of 5 stars
$101.95
-1.9%
$120.60
+18.3%
+0.2%$177.36B$40.11B31.76114,000Analyst Forecast
ISRG
Intuitive Surgical
4.3952 of 5 stars
$401.03
-0.9%
$396.17
-1.2%
+30.6%$142.25B$7.12B72.3913,676Analyst Forecast
Insider Selling
Short Interest ↑
BSX
Boston Scientific
4.6224 of 5 stars
$75.17
-0.6%
$75.41
+0.3%
+46.8%$110.28B$14.71B63.1748,000Analyst Forecast
Insider Selling
Short Interest ↓
MDT
Medtronic
4.8928 of 5 stars
$82.00
-0.4%
$94.00
+14.6%
-1.7%$108.88B$32.36B29.8295,000Analyst Forecast
BDX
Becton, Dickinson and Company
4.879 of 5 stars
$226.85
-0.8%
$281.40
+24.0%
-4.0%$65.56B$19.37B49.9773,000Analyst Forecast
Short Interest ↓
EW
Edwards Lifesciences
4.7508 of 5 stars
$87.04
-1.1%
$94.31
+8.4%
+3.2%$52.45B$6.00B37.5219,800Analyst Forecast
Insider Selling
Short Interest ↓
DXCM
DexCom
4.9594 of 5 stars
$127.38
+0.0%
$141.67
+11.2%
+1.3%$50.66B$3.62B82.189,600Analyst Forecast
Short Interest ↓
IDXX
IDEXX Laboratories
4.416 of 5 stars
$505.40
-2.1%
$580.38
+14.8%
+6.9%$41.74B$3.66B48.9311,000Positive News
RMD
ResMed
4.6111 of 5 stars
$207.17
-2.9%
$202.80
-2.1%
-2.1%$30.44B$4.22B31.8210,140Analyst Revision
STE
STERIS
4.0172 of 5 stars
$223.39
-2.5%
$241.60
+8.2%
+11.5%$22.07B$5.14B58.4817,100Analyst Downgrade
Analyst Revision

Related Companies and Tools

This page (NYSE:SYK) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners